121 related articles for article (PubMed ID: 22368299)
1. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.
Ghiorzo P; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bernard L; Bonelli L; Borgonovo G; Bruno W; De Cian F; Decensi A; Filauro M; Faravelli F; Gozza A; Gargiulo S; Mariette F; Nasti S; Pastorino L; Queirolo P; Savarino V; Varesco L; Scarrà GB;
J Med Genet; 2012 Mar; 49(3):164-70. PubMed ID: 22368299
[TBL] [Abstract][Full Text] [Related]
2. A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene.
Wong C; Chen F; Alirezaie N; Wang Y; Cuggia A; Borgida A; Holter S; Lenko T; Domecq C; ; Petersen GM; Syngal S; Brand R; Rustgi AK; Cote ML; Stoffel E; Olson SH; Roberts NJ; Akbari MR; Majewski J; Klein AP; Greenwood CMT; Gallinger S; Zogopoulos G
PLoS Genet; 2019 Aug; 15(8):e1008344. PubMed ID: 31469826
[TBL] [Abstract][Full Text] [Related]
3. The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.
Limijadi EKS; Muniroh M; Prajoko YW; Tjandra KC; Respati DRP
PLoS One; 2024; 19(5):e0299276. PubMed ID: 38809921
[TBL] [Abstract][Full Text] [Related]
4. Genetic predisposition to pancreatic cancer.
Ghiorzo P
World J Gastroenterol; 2014 Aug; 20(31):10778-89. PubMed ID: 25152581
[TBL] [Abstract][Full Text] [Related]
5. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
[TBL] [Abstract][Full Text] [Related]
6.
McWilliams RR; Wieben ED; Chaffee KG; Antwi SO; Raskin L; Olopade OI; Li D; Highsmith WE; Colon-Otero G; Khanna LG; Permuth JB; Olson JE; Frucht H; Genkinger J; Zheng W; Blot WJ; Wu L; Almada LL; Fernandez-Zapico ME; Sicotte H; Pedersen KS; Petersen GM
Cancer Epidemiol Biomarkers Prev; 2018 Nov; 27(11):1364-1370. PubMed ID: 30038052
[No Abstract] [Full Text] [Related]
7. Surgical outcomes after pancreatic surgery in patients with a germline CDKN2A/p16 pathogenic variant under surveillance.
Onnekink AM; Michiels N; Klatte DCF; Oldenburg L; Mieog JSD; Vahrmeijer AL; van Hooft JE; van Leerdam ME; Bonsing BA
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38156443
[No Abstract] [Full Text] [Related]
8. Familial Pancreatic Adenocarcinoma.
Petersen GM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):641-53. PubMed ID: 26226902
[TBL] [Abstract][Full Text] [Related]
9. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.
Zogopoulos G; Haimi I; Sanoba SA; Everett JN; Wang Y; Katona BW; Farrell JJ; Grossberg AJ; Paiella S; Klute KA; Bi Y; Wallace MB; Kwon RS; Stoffel EM; Wadlow RC; Sussman DA; Merchant NB; Permuth JB; Golan T; Raitses-Gurevich M; Lowy AM; Liau J; Jeter JM; Lindberg JM; Chung DC; Earl J; Brentnall TA; Schrader KA; Kaul V; Huang C; Chandarana H; Smerdon C; Graff JJ; Kastrinos F; Kupfer SS; Lucas AL; Sears RC; Brand RE; Parmigiani G; Simeone DM;
J Natl Compr Canc Netw; 2024 Apr; 22(3):158-166. PubMed ID: 38626807
[TBL] [Abstract][Full Text] [Related]
10. Association of Glycated Hemoglobin With a Risk of Pancreatic Cancer in High-Risk Individuals Based on Genetic and Family History.
Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.
Leof ER; Zhu X; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
Genet Med; 2019 Nov; 21(11):2468-2477. PubMed ID: 30992552
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer.
Paiella S; Capurso G; Carrara S; Secchettin E; Casciani F; Frigerio I; Zerbi A; Archibugi L; Bonifacio C; Malleo G; Cavestro GM; Barile M; Larghi A; Assisi D; Fantin A; Milanetto AC; Fabbri C; Casadei R; Donato G; Sassatelli R; De Marchi G; Di Matteo FM; Arcangeli V; Panzuto F; Puzzono M; Dal Buono A; Pezzilli R; Salvia R; Rizzatti G; Casadio M; Franco M; Butturini G; Pasquali C; Coluccio C; Ricci C; Cicchese N; Sereni G; de Pretis N; Stigliano S; Rudnas B; Marasco M; Lionetto G; Arcidiacono PG; Terrin M; Crovetto A; Mannucci A; Laghi L; Bassi C; Falconi M
Am J Gastroenterol; 2024 Apr; 119(4):739-747. PubMed ID: 37787643
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of Individuals with a Family History of Pancreatic Cancer and Inherited Cancer Syndromes: A Strategy for Detecting Early Pancreatic Cancers.
Matsubayashi H; Kiyozumi Y; Ishiwatari H; Uesaka K; Kikuyama M; Ono H
Diagnostics (Basel); 2019 Oct; 9(4):. PubMed ID: 31683730
[TBL] [Abstract][Full Text] [Related]
14. Familial pancreatic cancer: a case study and review of the psychosocial effects of diagnoses on families.
Lowe T; DeLuca J; Abenavoli L; Boccuto L
Hered Cancer Clin Pract; 2023 Sep; 21(1):17. PubMed ID: 37684686
[TBL] [Abstract][Full Text] [Related]
15. The Italian registry of families at risk for pancreatic cancer (IRFARPC): implementation and evolution of a national program for pancreatic cancer surveillance in high-risk individuals.
Archibugi L; Casciani F; Carrara S; Secchettin E; Falconi M; Capurso G; Paiella S
Fam Cancer; 2024 Mar; ():. PubMed ID: 38493228
[TBL] [Abstract][Full Text] [Related]
16. The odyssee from surveillance to the detection of pancreatic cancer, total pancreatectomy, and its impact on life. insights from a p16-Leiden pathogenic variant carrier.
Spruitenburg AM; Vasen HF
Fam Cancer; 2024 Apr; ():. PubMed ID: 38662261
[No Abstract] [Full Text] [Related]
17. Rare mutations in XRCC2 increase the risk of breast cancer.
Park DJ; Lesueur F; Nguyen-Dumont T; Pertesi M; Odefrey F; Hammet F; Neuhausen SL; John EM; Andrulis IL; Terry MB; Daly M; Buys S; Le Calvez-Kelm F; Lonie A; Pope BJ; Tsimiklis H; Voegele C; Hilbers FM; Hoogerbrugge N; Barroso A; Osorio A; ; ; Giles GG; Devilee P; Benitez J; Hopper JL; Tavtigian SV; Goldgar DE; Southey MC
Am J Hum Genet; 2012 Apr; 90(4):734-9. PubMed ID: 22464251
[TBL] [Abstract][Full Text] [Related]
18. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
[TBL] [Abstract][Full Text] [Related]
19. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers.
Iqbal J; Ragone A; Lubinski J; Lynch HT; Moller P; Ghadirian P; Foulkes WD; Armel S; Eisen A; Neuhausen SL; Senter L; Singer CF; Ainsworth P; Kim-Sing C; Tung N; Friedman E; Llacuachaqui M; Ping S; Narod SA;
Br J Cancer; 2012 Dec; 107(12):2005-9. PubMed ID: 23099806
[TBL] [Abstract][Full Text] [Related]
20. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Infante JR; Somer BG; Park JO; Li CP; Scheulen ME; Kasubhai SM; Oh DY; Liu Y; Redhu S; Steplewski K; Le N
Eur J Cancer; 2014 Aug; 50(12):2072-81. PubMed ID: 24915778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
